Novel urinary protein panels for the non‐invasive diagnosis of non‐alcoholic fatty liver disease and fibrosis stages

There is an unmet clinical need for non‐invasive tests to diagnose non‐alcoholic fatty liver disease (NAFLD) and individual fibrosis stages. We aimed to test whether urine protein panels could be used to identify NAFLD, NAFLD with fibrosis (stage F ≥ 1) and NAFLD with significant fibrosis (stage F ≥ 2).

[1]  Shi Wang,et al.  Urine Proteome in Distinguishing Hepatic Steatosis in Patients with Metabolic-Associated Fatty Liver Disease , 2022, Diagnostics.

[2]  T. Ahluwalia,et al.  Urinary Proteomics Identifies Cathepsin D as a Biomarker of Rapid eGFR Decline in Type 1 Diabetes. , 2022, Diabetes care.

[3]  M. Zheng,et al.  Ferroptosis and metabolic dysfunction‐associated fatty liver disease: Is there a link? , 2022, Liver international : official journal of the International Association for the Study of the Liver.

[4]  C. Kraft,et al.  Quantitative high-confidence human mitochondrial proteome and its dynamics in cellular context , 2021, Cell metabolism.

[5]  L. Poretsky,et al.  Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD) , 2021, Metabolism open.

[6]  Shougang Wei,et al.  Integrated metabolomics and proteomics analysis reveals energy metabolism disorders in the livers of sleep-deprived mice. , 2021, Journal of proteomics.

[7]  V. Wong,et al.  Consensus scoring systems for nonalcoholic fatty liver disease: an unmet clinical need. , 2021, Hepatobiliary surgery and nutrition.

[8]  J. Totoń-Żurańska,et al.  Diminazene Aceturate Stabilizes Atherosclerotic Plaque and Attenuates Hepatic Steatosis in apoE-Knockout Mice by Influencing Macrophages Polarization and Taurine Biosynthesis , 2021, International journal of molecular sciences.

[9]  G. Arrigoni,et al.  Protein profile of commercial soybean milks analyzed by label-free quantitative proteomics. , 2021, Food chemistry.

[10]  J. Combier,et al.  Recent advances in mass spectrometry-based peptidomics workflows to identify short-open-reading-frame-encoded peptides and explore their functions. , 2021, Current opinion in chemical biology.

[11]  N. Pyrsopoulos,et al.  Diversity in NAFLD: A Review of Manifestations of Nonalcoholic Fatty Liver Disease in Different Ethnicities Globally , 2020, Journal of clinical and translational hepatology.

[12]  Chengde Yang,et al.  Urinary Proteomics Identifying Novel Biomarkers for the Diagnosis of Adult-Onset Still’s Disease , 2020, Frontiers in Immunology.

[13]  R. Wilkinson,et al.  Comprehensive plasma proteomic profiling reveals biomarkers for active tuberculosis , 2020, JCI insight.

[14]  Maximilian T. Strauss,et al.  Urinary proteome profiling for stratifying patients with familial Parkinson’s disease , 2020, bioRxiv.

[15]  Weiqi Wang,et al.  The protective effects of the β3 adrenergic receptor agonist BRL37344 against liver steatosis and inflammation in a rat model of high-fat diet-induced nonalcoholic fatty liver disease (NAFLD) , 2020, Molecular medicine.

[16]  S. Greenberg,et al.  NAFLD Epidemiology, Emerging Pharmacotherapy, Liver Transplantation Implications and the Trends in the United States , 2020, Journal of clinical and translational hepatology.

[17]  Hengliang Wang,et al.  Urine proteome of COVID-19 patients , 2020, URINE.

[18]  Qing-feng Chen,et al.  Platelet count is closely associated with the severity of liver injury in patients with chronic hepatitis B virus infection: A cross-sectional study , 2020, Experimental and therapeutic medicine.

[19]  Hui-hong Yu,et al.  Inhibition of stearoyl-coenzyme A desaturase 1 ameliorates hepatic steatosis by inducing AMPK-mediated lipophagy , 2020, Aging.

[20]  S. Nicholas.  Use of urinary proteomics in diagnosis and monitoring of diabetic kidney disease. , 2020, The lancet. Diabetes & endocrinology.

[21]  Utpal Anand,et al.  Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations , 2019, Journal of clinical and translational hepatology.

[22]  Melanie C. McKell,et al.  Macrophage Function in the Pathogenesis of Non-alcoholic Fatty Liver Disease: The Mac Attack , 2019, Front. Immunol..

[23]  Yuxin Yin,et al.  Plasma proteomics-based identification of novel biomarkers in early gastric cancer. , 2019, Clinical biochemistry.

[24]  M. Schrader,et al.  Co-regulation map of the human proteome enables identification of protein functions , 2019, Nature Biotechnology.

[25]  M. Zheng,et al.  Individualized risk prediction of significant fibrosis in non-alcoholic fatty liver disease using a novel nomogram , 2019, United European gastroenterology journal.

[26]  Hae-Jeung Lee,et al.  Lonicera caerulea Extract Attenuates Non-Alcoholic Fatty Liver Disease in Free Fatty Acid-Induced HepG2 Hepatocytes and in High Fat Diet-Fed Mice , 2019, Nutrients.

[27]  S. Mandrup,et al.  Transcriptional regulation of Hepatic Stellate Cell activation in NASH , 2019, Scientific Reports.

[28]  M. Zheng,et al.  A simpler diagnostic formula for screening nonalcoholic fatty liver disease. , 2019, Clinical biochemistry.

[29]  Antonio Felix Conde-Martin,et al.  Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. , 2018, Gastroenterology.

[30]  Kai Huang,et al.  Enoyl coenzyme A hydratase 1 protects against high-fat-diet-induced hepatic steatosis and insulin resistance. , 2018, Biochemical and biophysical research communications.

[31]  R. Hultcrantz,et al.  Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. , 2017, Journal of hepatology.

[32]  Yuehua Wu,et al.  Activation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis , 2017, Nature Medicine.

[33]  Yiming Lin,et al.  Fatty acids promote fatty liver disease via the dysregulation of 3-mercaptopyruvate sulfurtransferase/hydrogen sulfide pathway , 2017, Gut.

[34]  Tianxin Lin,et al.  A Radiomics Nomogram for the Preoperative Prediction of Lymph Node Metastasis in Bladder Cancer , 2017, Clinical Cancer Research.

[35]  Joseph M Pappachan,et al.  Non-alcoholic Fatty Liver Disease: A Clinical Update , 2017, Journal of clinical and translational hepatology.

[36]  A. McCullough,et al.  Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease , 2017, Journal of clinical and translational hepatology.

[37]  V. Wong,et al.  Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis , 2017, Hepatology.

[38]  Matthew V. Holt,et al.  Proof-of-Concept Workflow for Establishing Reference Intervals of Human Urine Proteome for Monitoring Physiological and Pathological Changes , 2017, EBioMedicine.

[39]  Jüergen Cox,et al.  The MaxQuant computational platform for mass spectrometry-based shotgun proteomics , 2016, Nature Protocols.

[40]  Yanqi Huang,et al.  Development and Validation of a Radiomics Nomogram for Preoperative Prediction of Lymph Node Metastasis in Colorectal Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Timothy R Lezon,et al.  Proteomic Screening and Lasso Regression Reveal Differential Signaling in Insulin and Insulin-like Growth Factor I (IGF1) Pathways * , 2016, Molecular & Cellular Proteomics.

[42]  P. Bedossa,et al.  Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease. , 2016, Gastroenterology.

[43]  Michael Olusegun Akinwande,et al.  Variance Inflation Factor: As a Condition for the Inclusion of Suppressor Variable(s) in Regression Analysis , 2015 .

[44]  E. Bjornsson,et al.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.

[45]  M. Maes,et al.  Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research. , 2015, Progress in lipid research.

[46]  Mats Fredrikson,et al.  Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.

[47]  B. Sitek,et al.  Label-free quantification in clinical proteomics. , 2013, Biochimica et biophysica acta.

[48]  N. Rizk,et al.  Genetic polymorphisms of ICAM 1 and IL28 as predictors of liver fibrosis severity and viral clearance in hepatitis C genotype 4. , 2013, Clinics and research in hepatology and gastroenterology.

[49]  Julien Boccard,et al.  A consensus orthogonal partial least squares discriminant analysis (OPLS-DA) strategy for multiblock Omics data fusion. , 2013, Analytica chimica acta.

[50]  Udo Hoffmann,et al.  Genome-Wide Association Analysis Identifies Variants Associated with Nonalcoholic Fatty Liver Disease That Have Distinct Effects on Metabolic Traits , 2011, PLoS genetics.

[51]  Hesheng Luo,et al.  Effects of Thalidomide on the Expression of Adhesion Molecules in Rat Liver Cirrhosis , 2006, Mediators of inflammation.

[52]  A. Baranova,et al.  A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease , 2005, Hepatology.

[53]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[54]  A. Lonardo,et al.  Liver fibrosis in nonalcoholic fatty liver disease patients: noninvasive evaluation and correlation with cardiovascular disease and mortality , 2023, Metabolism and Target Organ Damage.